FORM 6-K


U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For the month of June 2023

 Commission File Number: 001-38757
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)

1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F  ☒            Form 40-F  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐


Information furnished on this form:
EXHIBIT



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: June 23, 2023By:/s/ Norimasa Takeda
Norimasa Takeda
Chief Accounting Officer and Corporate Controller


June 23, 2023
Dear Shareholders
Christophe Weber
President and Representative Director
Takeda Pharmaceutical Company Limited
1-1, Doshomachi 4-chome
Chuo-ku, Osaka
Partial Correction to the Notice of Convocation of the 147th Ordinary General Meeting of Shareholders
Takeda Pharmaceutical Company Limited (the “Company”) hereby reports that there is a part to be corrected in the Notice of Convocation of the 147th Ordinary General Meeting of Shareholders (the “Notice”) and that the Company therefore decided to make a correction to the said part as described herein below.
1.Correction part:
The number of Company Shares owned by Mr. Christophe Weber, which is described in the Second Proposal (page 8) in the “Reference Document for the General Meeting of Shareholders” of the Notice
2.Contents of the correction:
(Underlined sections indicate changes)
Before correction
Number of Company Shares Owned
378,100 shares
↓
After correction
Number of Company Shares Owned
628,100 shares
[End of document]

Takeda Pharmaceutical (PK) (USOTC:TKPHF)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Takeda Pharmaceutical (PK)
Takeda Pharmaceutical (PK) (USOTC:TKPHF)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Takeda Pharmaceutical (PK)